Global Blood Therapeutics
171 Oyster Point Blvd., Suite 300
South San Francisco
California
94080
United States
Website: http://www.gbt.com/
Email: info@gbt.com
About Global Blood Therapeutics
GBT is a biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing two therapies for the potential treatment of sickle cell disease, including its late-stage product candidate, voxelotor, as an oral, once-daily therapy. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
129 articles with Global Blood Therapeutics
-
GBT Announces Results of Post-hoc Analysis of Phase 3 HOPE Study Showing Improvement in Leg Ulcers in Patients with Sickle Cell Disease Treated with Voxelotor
10/21/2019
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced results of a post-hoc analysis of data from the Phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study of voxelotor, an oral, once-daily therapy in development for the treatment of sickle cell disease (SCD).
-
GBT Announces New Employment Inducement Grants on October 1, 2019
10/7/2019
Global Blood Therapeutics, Inc., announced that on October 1, 2019, the compensation committee of GBT’s board of directors granted 12 new employees options to purchase an aggregate of 24,600 shares of the company’s common stock with a per share exercise price of $46.99 and restricted stock units for an aggregate of 57,050 shares of the company’s common stock.
-
GBT Announces Upcoming Presentations at the 47th Annual National Sickle Cell Disease Association of America (SCDAA) Convention
10/2/2019
Global Blood Therapeutics, Inc. announced that four abstracts related to its sickle cell disease research have been accepted for oral and poster presentations during the 47th Annual National Sickle Cell Disease Association of America Convention in Baltimore, taking place October 9-12, 2019.
-
GBT to Host Analyst & Investor Day on October 8 in New York
10/1/2019
Global Blood Therapeutics, Inc., announced that it will host an Analyst & Investor Day to provide an update to the investment community on the company’s development and commercial strategy for voxelotor for sickle cell disease.
-
Top 12 Biotech Companies Hiring Now
10/1/2019
Fall frenzy is heading our way! Check out the top companies who are looking for candidates like you right now! -
GBT Announces Participation at the 2019 Cantor Global Healthcare Conference
9/25/2019
Global Blood Therapeutics, Inc. announced that it will present at the 2019 Cantor Global Healthcare Conference in New York City on Wednesday, October 2, 2019, at 10:05 a.m. Eastern Time.
-
GBT Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Voxelotor for the Treatment of Sickle Cell Disease
9/5/2019
Global Blood Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) seeking accelerated approval for voxelotor, an oral, once-daily therapy in development for the treatment of sickle cell disease (SCD).
-
GBT Announced on September 1, 2019 New Employment Inducement Grants
9/4/2019
Global Blood Therapeutics, Inc. announced that on September 1, 2019, the compensation committee of GBT’s board of directors granted Eric Fink and 8 new employees options to purchase an aggregate of 47,600 shares of the company’s common stock with a per share exercise price of $45.98 and restricted stock units for an aggregate of 54,425 shares of the company’s common stock.
-
GBT Announces Participation at the 2019 Morgan Stanley Global Healthcare Conference
9/3/2019
Global Blood Therapeutics, Inc. announced that it will present at the 2019 Morgan Stanley Global Healthcare Conference in New York City on Monday, September 9, 2019, at 2:50 p.m. Eastern Time.
-
GBT and Sickle Cell Disease Association of America to Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference
9/3/2019
Global Blood Therapeutics, Inc. and the Sickle Cell Disease Association of America, Inc. announced that they will host the 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Tuesday, September 10, 2019, at The Westin Washington, D.C. U.S. Representative Robin Kelly, chair of the Congressional Black Caucus Health Braintrust, will deliver the keynote address.
-
GBT Reports Recent Business Progress and Second Quarter 2019 Financial Results
8/7/2019
Global Blood Therapeutics, Inc. reported recent business progress and financial results for the second quarter ended June 30, 2019.
-
GBT Announces Participation at the 2019 Wedbush PacGrow Healthcare Conference
8/6/2019
Global Blood Therapeutics, Inc. announced that it will present at the 2019 Wedbush PacGrow Healthcare Conference in New York City on Tuesday, August 13, 2019, at 1:55 p.m. Eastern Time.
-
According to a BioSpace poll, approximately 86% of life science respondents are on the verge of job burnout. Are you one of the 86%? Does this mean you need to start looking for a new job? This is definitely one of your options. Start here to look at all of the great opportunities out there in t...
-
GBT Announces New Employment Inducement Grants - August 02, 2019
8/4/2019
Global Blood Therapeutics, Inc. announced that on August 1, 2019, the compensation committee of GBT’s board of directors granted 14 new employees options to purchase an aggregate of 26,200 shares of the company’s common stock with a per share exercise price of $54.25 and restricted stock units for an aggregate of 69,450 shares of the company’s common stock.
-
GBT and Advocates Launch Disease Awareness Campaign Focused on Breaking Down Stigmas Associated with Sickle Cell Disease
7/10/2019
Company Also Launches Disease Awareness Campaign to Raise Awareness Among Physicians About the Silent Damage Caused by Sickle Cell Disease
-
GBT Announces New Employment Inducement Grants - July 09, 2019
7/9/2019
Global Blood Therapeutics, Inc. announced that on July 1, 2019, the compensation committee of GBT’s board of directors granted 13 new employees options to purchase an aggregate of 4,000 shares of the company’s common stock with a per share exercise price of $53.93 and restricted stock units for an aggregate of 31,700 shares of the company’s common stock.
-
According to a BioSpace poll, over half (56%) of respondents are not happy with their current life sciences position. Are you one of the 56%? You deserve to be happy! Start working towards your happiness and check out job opportunities at these top companies!
-
Global Blood Therapeutics Prices a $200.0 Million Common Stock Public Offering
6/26/2019
Global Blood Therapeutics, Inc. announced the pricing of its underwritten public offering of 3,375,527 shares of its common stock for gross proceeds of approximately $200.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by GBT.
-
Global Blood Therapeutics Announces Proposed Public Offering of $200.0 Million in Shares of its Common Stock
6/25/2019
Global Blood Therapeutics, Inc. announced an agreement to sell approximately $200.0 million in shares of its common stock in a registered underwritten public offering.
-
Clinical Catch-up for June 10-14
6/17/2019
Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look.